Abby Hardy, Author at BioTuesdays

Developments

Humanigen reports positive interim data from Phase 3 COVID-19 trial

Humanigen (NASDAQ:HGEN) reported positive interim results from its Phase 3 trial evaluating lenzilumab in hospitalized COVID-19 patients. Lenzilumab is an antibody that targets granulocyte-macrophage colony-stimulating...

November 6, 2020

Developments

LogicBio gets FDA fast track designation for methylmalonic acidemia

LogicBio Therapeutics’ (NASDAQ:LOGC) LB-001 received FDA fast track designation for the treatment of methylmalonic acidemia (MMA). MMA is caused by a mutation in genes responsible for the breakdown of certain proteins...

November 4, 2020

Developments

Cassava Sciences reports additional data from Phase 2b Alzheimer’s disease trial

Cassava Sciences (NASDAQ:SAVA) reported additional data from its Phase 2b study of sumifilam for the treatment of Alzheimer’s disease (AD). The study enrolled 64 patients with mild-to-moderate AD, 50-to-85 years of age...

November 4, 2020

Executive Moves

LogicBio names Mariana Nacht as CSO; Kyle Chiang as COO

LogicBio Therapeutics (NASDAQ:LOGC) appointed Mariana Nacht, Ph.D., as CSO, effective Nov. 30; and promoted Kyle Chiang, Ph.D., to the role of COO, effective Nov. 2. The company is expanding its leadership team to...

November 3, 2020

Executive Moves

Aethlon Medical names Charles Fisher as CEO

Aethlon Medical (NASDAQ:AEMD) appointed Charles Fisher, M.D., as CEO, effective Oct. 30. Dr. Fisher joined Aethlon as a member of its board and served as its chairman since November 2017. He succeeds Dr. Timothy Rodell...

November 3, 2020

Developments

Concert Pharmaceuticals launches Phase 3 alopecia areata trial

Concert Pharmaceuticals (NASDAQ:CNCE) initiated a Phase 3 trial to evaluate CTP-543 for the treatment of alopecia areata. Alopecia areata is an autoimmune disease that causes partial or complete loss of hair on the...

November 3, 2020

Executive Moves

iBio appoints global biotech operations expert, Randy Maddux, as COO

Randy Maddux iBio (NYSE AMERICAN:IBIO) appointed biotech industry veteran, Randy Maddux, as COO, effective Dec. 1. Mr. Maddux has more than 20 years of global biologics drug development and manufacturing, business...

November 3, 2020

Feature

Micron developing microneedle technology for self-administration of vaccines and therapeutics

Closely-held Micron Biomedical is developing a dissolvable microneedle-based technology that could enable self-administration of vaccines and therapeutics.

November 3, 2020

Developments

Titan Pharma completes debt settlement with Molteni and Horizon; acquisition of JT-09

Titan Pharmaceuticals (NASDAQ:TTNP) settled all of its debt obligations with Molteni & C. dei F.lli Alitti Società di Esercizio and Horizon Credit, as well as the acquisition of JT Pharmaceuticals’ JT-09. Completion...

November 2, 2020

Developments

Zucara Expands ZT-01 Development to Type 2 Diabetes

Closely-held Zucara Therapeutics is expanding the development of ZT-01, which is currently in a Phase 1 trial for the prevention of insulin-induced hypoglycemia in patients with Type 1 Diabetes...

November 2, 2020

Author - Abby Hardy

Humanigen reports positive interim data from Phase 3 COVID-19 trial

LogicBio gets FDA fast track designation for methylmalonic acidemia

Cassava Sciences reports additional data from Phase 2b Alzheimer’s disease trial

LogicBio names Mariana Nacht as CSO; Kyle Chiang as COO

Aethlon Medical names Charles Fisher as CEO

Concert Pharmaceuticals launches Phase 3 alopecia areata trial

iBio appoints global biotech operations expert, Randy Maddux, as COO

Micron developing microneedle technology for self-administration of vaccines and therapeutics

Titan Pharma completes debt settlement with Molteni and Horizon; acquisition of JT-09

Zucara Expands ZT-01 Development to Type 2 Diabetes

General

More